BlackRock Investment Management’s Theravance Biopharma TBPH Stock Holding History

BlackRock Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.61M	Buy	144,619 +9,354	+7%	+$290K	0.01%	1637
2016 Q3	$4.9M	Sell	135,265 -184	-0.1%	-$5.12K	0.01%	1495
2016 Q2	$3.07M	Buy	135,449 +21,149	+19%	+$457K	﹤0.01%	1789
2016 Q1	$2.15M	Buy	114,300 +11,717	+11%	+$192K	﹤0.01%	1948
2015 Q4	$1.68M	Buy	102,583 +5,490	+6%	+$87.1K	﹤0.01%	2216
2015 Q3	$1.07M	Sell	97,093 -398	-0.4%	-$5.07K	﹤0.01%	2557
2015 Q2	$1.27M	Buy	97,491 +28,420	+41%	+$441K	﹤0.01%	2599
2015 Q1	$1.2M	Buy	69,071 +583	+0.9%	+$10.7K	﹤0.01%	2408
2014 Q4	$1.02M	Sell	68,488 -525	-0.8%	-$9.15K	﹤0.01%	2535
2014 Q3	$1.59M	Buy	69,013 +306	+0.4%	+$8.88K	﹤0.01%	2175
2014 Q2	$2.19M	Buy	+68,707	New	+$2.07M	﹤0.01%	2013

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Investment Management's TBPH Position: Q4 2016 in Review

BlackRock Investment Management increased its Theravance Biopharma (TBPH) stake by 6.9% in Q4 2016, buying an estimated $290K and bringing the position to 144,619 shares worth $4.61M. The position accounts for 0.01% of the portfolio, ranked #1637.

BlackRock Investment Management first reported a position in TBPH in Q2 2014 and has held it in 11 quarters since. The position peaked at $4.9M in Q3 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

BlackRock Investment Management held 144,619 shares of Theravance Biopharma worth $4.61M as of Q4 2016.
BlackRock Investment Management bought 9,354 Theravance Biopharma shares in Q4 2016, an estimated $290K.
Theravance Biopharma made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1637 holding.
BlackRock Investment Management first reported a position in Theravance Biopharma in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Theravance Biopharma position peaked at $4.9M in Q3 2016.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.